Management of persistent idiopathic facial pain (PIFP) – An international Delphi study

Background/AimPersistent idiopathic facial pain (PIFP) is a rare condition with a lifetime prevalence of approximately 0.03%. It is characterized by persistent daily facial pain without identifiable cause and presents diagnostic and therapeutic challenges due to unknown pathophysiology, symptom overlap with other painful disorders, and limited evidence-based treatments. The aim of this Delphi study was to establish international consensus-derived guidelines for the management of patients with PIFP.MethodsA three-round Delphi study was conducted with 16 international pain experts, each with ≥10 years of clinical experience in pain management and extensive peer-reviewed publications. The first round involved open-ended questions, and the qualitative data were analyzed using systematic text condensation, resulting in a quantitative questionnaire with 42 statements. Subsequent rounds employed Likert-scale responses to these statements. Consensus was defined as ≥80% agreement or disagreement. In addition, if 11-12 (68-75 percent) out of the 16 experts agreed or disagreed, consensus was not reached, but a majority was considered to have a particular opinion.ResultsConsensus was reached in 35 out of the 42 statements (83%), emphasizing multidisciplinary collaboration and avoidance of invasive procedures in the treatment of PIFP. In an additional three statements (7%) a majority of the experts agreed with each other. In four statements (10%), no consensus or majority was reached. Pharmacological treatments, including tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids, may be considered; however, opioids should generally be avoided in the treatment of PIFP. Patient education and behavioral therapies are important interventions, and the most important measure of therapeutic success is improved quality of lifeConclusionThe present Delphi study has established internationally derived consensus guidelines and recommendations for the evaluation and comprehensive management of patients with PIFP. This is a first step in gathering knowledge for future evidence-based guidelines and more specific treatment recommendations. These international expert consensus guidelines recommend a multi- or interdisciplinary approach in managing PIFP, avoiding invasive interventions and prioritizing patient-centered outcomes.

Authors

Institutions

Publication Details

Journal
Cephalalgia
Published
2025-12-01
DOI
https://doi.org/10.1177/03331024251399927
Citations
2
Primary Topic
Temporomandibular Joint Disorders
Type
article
Field-Weighted Citation Impact
4.28
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Management of persistent idiopathic facial pain (PIFP) – An international Delphi study

Justin Durham, Donald R. Nixdorf, Rafael Benoliel, Paulo César Rodrigues Conti et al.
2 citations
Cephalalgia
Temporomandibular Joint Disorders
4.28
article

Management of persistent idiopathic facial pain (PIFP) – An international Delphi study

Justin Durham, Donald R. Nixdorf, Rafael Benoliel, Paulo César Rodrigues Conti, Arne May, Rolf‐Detlef Treede, Tara Renton, Joanna M. Zakrzewska, Thomas List, Peter Svensson, Osamu Komiyama, Torsten Gordh, Per Alstergren, Gunnar Skagerberg, Maria Pigg, Jens C. Türp, Dimos D. Mitsikostas, Jean‐Paul Goulet, Erik Lindfors
article en
2 citations

Abstract

Background/AimPersistent idiopathic facial pain (PIFP) is a rare condition with a lifetime prevalence of approximately 0.03%. It is characterized by persistent daily facial pain without identifiable cause and presents diagnostic and therapeutic challenges due to unknown pathophysiology, symptom overlap with other painful disorders, and limited evidence-based treatments. The aim of this Delphi study was to establish international consensus-derived guidelines for the management of patients with PIFP.MethodsA three-round Delphi study was conducted with 16 international pain experts, each with ≥10 years of clinical experience in pain management and extensive peer-reviewed publications. The first round involved open-ended questions, and the qualitative data were analyzed using systematic text condensation, resulting in a quantitative questionnaire with 42 statements. Subsequent rounds employed Likert-scale responses to these statements. Consensus was defined as ≥80% agreement or disagreement. In addition, if 11-12 (68-75 percent) out of the 16 experts agreed or disagreed, consensus was not reached, but a majority was considered to have a particular opinion.ResultsConsensus was reached in 35 out of the 42 statements (83%), emphasizing multidisciplinary collaboration and avoidance of invasive procedures in the treatment of PIFP. In an additional three statements (7%) a majority of the experts agreed with each other. In four statements (10%), no consensus or majority was reached. Pharmacological treatments, including tricyclic antidepressants, serotonin-norepinephrine reuptake inhibitors, and gabapentinoids, may be considered; however, opioids should generally be avoided in the treatment of PIFP. Patient education and behavioral therapies are important interventions, and the most important measure of therapeutic success is improved quality of lifeConclusionThe present Delphi study has established internationally derived consensus guidelines and recommendations for the evaluation and comprehensive management of patients with PIFP. This is a first step in gathering knowledge for future evidence-based guidelines and more specific treatment recommendations. These international expert consensus guidelines recommend a multi- or interdisciplinary approach in managing PIFP, avoiding invasive interventions and prioritizing patient-centered outcomes.

CephalalgiaVol. 45(12)
Rutgers, The State University of New Jersey (US), Nihon University (JP), Uppsala University (SE), University of Minnesota (US), Universität Hamburg (DE), National University of Singapore (SG), Universidade de São Paulo (BR), Malmö University (SE), King's College London (GB), University of Basel (CH), Lund University (SE), National and Kapodistrian University of Athens (GR), Heidelberg University (DE), University Hospital of Basel (CH), Public Dental Service Västra Götaland (SE), Central Institute of Mental Health (DE), University Medical Center Hamburg-Eppendorf (DE), Bernstein Center for Computational Neuroscience Heidelberg-Mannheim (DE), Department of Biomedicine Basel (CH), Skåne University Hospital (SE), Eastman Chemical Company (United States) (US), Eginition Hospital (GR), National Hospital for Neurology and Neurosurgery (GB), Eastman Dental Hospital (GB), Université Laval (CA), University College London (GB), University of Rochester (US), Newcastle University (GB)
Openalex Percentile: Top 5%
Temporomandibular Joint Disorders
4.28
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.